American Urological Association - Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

advertisement

Home Guidelines Archived Documents Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

AHA/ACS/AUA Science Advisory: Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk [pdf]
Published 2010

Androgen-deprivation therapy (ADT) is a treatment widely used in the management of prostate cancer. Several studies have recently reported an association between ADT and an increased risk of cardiovascular events. This multidisciplinary document produced through collaboration between the American Heart Association, the American Cancer Society, and the AUA reviews the data regarding the possible relationship between ADT and cardiovascular events in patients with prostate cancer and includes suggesions regarding the evaluation and management of such patients.

advertisement

advertisement

The New AUAnet

Tips

Website Tip!

While viewing Guideline Statements on a desktop computer, use the left navigation to jump to different parts of the page.